(PDEX) Pro-Dex - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 208m USD | Total Return: 57.2% in 12m
Avg Turnover: 3.53M
EPS Trend: 84.0%
Qual. Beats: 1
Rev. Trend: 99.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Shakeout, Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
Pro-Dex, Inc. (PDEX) specializes in the design and manufacture of powered surgical instruments, primarily serving medical device original equipment manufacturers (OEMs). The company’s product portfolio includes autoclavable, electric, and battery-powered drivers and shavers utilized in orthopedic, thoracic, and craniomaxillofacial surgeries. Beyond hardware, the firm provides regulatory consulting and engineering services to its clients.
Operating within the Health Care Equipment sub-industry, Pro-Dex utilizes a B2B business model where revenue is largely driven by long-term supply agreements with larger medical technology firms. The specialized nature of autoclavable power tools requires high-precision engineering to withstand repeated sterilization cycles without mechanical failure. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation metrics.
Founded in 1978 and headquartered in Irvine, California, the company also produces rotary air motors for industrial applications. Its customer base spans hospitals, scientific research facilities, and high-tech manufacturing labs globally.
- Surgical instrument OEM contract renewals drive long-term revenue stability
- Gross margin expansion through manufacturing efficiency and product mix optimization
- New product launches in orthopedic and thoracic markets accelerate growth
- Regulatory compliance and FDA approvals facilitate market entry for new devices
| Net Income: 12.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 12.15 > 1.0 |
| NWC/Revenue: 52.35% < 20% (prev 49.32%; Δ 3.03% < -1%) |
| CFO/TA 0.10 > 3% & CFO 7.34m > Net Income 12.0m |
| Net Debt (10.0m) to EBITDA (19.6m): 0.51 < 3 |
| Current Ratio: 3.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.27m) vs 12m ago -2.03% < -2% |
| Gross Margin: 27.78% > 18% (prev 31.36%; Δ -3.58% > 0.5%) |
| Asset Turnover: 107.2% > 50% (prev 99.77%; Δ 7.43% > 0%) |
| Interest Coverage Ratio: 22.56 > 6 (EBIT TTM 17.4m / Interest Expense TTM 769k) |
| A: 0.52 (Total Current Assets 53.7m - Total Current Liabilities 14.6m) / Total Assets 75.0m |
| B: 0.60 (Retained Earnings 45.2m / Total Assets 75.0m) |
| C: 0.25 (EBIT TTM 17.4m / Avg Total Assets 69.6m) |
| D: 1.52 (Book Value of Equity 45.2m / Total Liabilities 29.8m) |
| Altman-Z'' = 8.65 = AAA |
| DSRI: 1.07 (Receivables 19.8m/15.9m, Revenue 74.6m/64.1m) |
| GMI: 1.13 (GM 31.36% / 27.78%) |
| AQI: 1.34 (AQ_t 0.27 / AQ_t-1 0.20) |
| SGI: 1.16 (Revenue 74.6m / 64.1m) |
| TATA: 0.06 (NI 12.0m - CFO 7.34m) / TA 75.0m) |
| Beneish M = -2.53 (Cap -4..+1) = A |
As of June 15, 2026, the stock is trading at USD 62.20 with a total of 99,816 shares traded.
Over the past week, the price has changed by -4.62%,
over one month by +8.29%,
over three months by +28.35% and
over the past year by +57.23%.
Pro-Dex has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy PDEX.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 70 | 12.5% |
P/E Trailing = 17.9063
P/E Forward = 23.6407
P/S = 2.7805
P/B = 4.641
Revenue TTM = 74.6m USD
EBIT TTM = 17.4m USD
EBITDA TTM = 19.6m USD
Long Term Debt = 14.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.03m USD (from shortTermDebt, last quarter)
Debt = 21.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 838k
Net Debt = 10.0m USD (calculated: Debt 21.0m - CCE 11.0m)
Enterprise Value = 217.6m USD (207.5m + Debt 21.0m - CCE 11.0m)
Interest Coverage Ratio = 22.56 (Ebit TTM 17.4m / Interest Expense TTM 769k)
EV/FCF = 30.79x (Enterprise Value 217.6m / FCF TTM 7.07m)
FCF Yield = 3.25% (FCF TTM 7.07m / Enterprise Value 217.6m)
FCF Margin = 9.47% (FCF TTM 7.07m / Revenue TTM 74.6m)
Net Margin = 16.08% (Net Income TTM 12.0m / Revenue TTM 74.6m)
Gross Margin = 27.78% ((Revenue TTM 74.6m - Cost of Revenue TTM 53.9m) / Revenue TTM)
Gross Margin QoQ = 30.74% (prev 30.77%)
Tobins Q-Ratio = 2.90 (Enterprise Value 217.6m / Total Assets 75.0m)
Interest Expense / Debt = 3.66% (Interest Expense 769k / Debt 21.0m)
Taxrate = 25.41% (4.09m / 16.1m)
NOPAT = 12.9m (EBIT 17.4m * (1 - 25.41%))
Current Ratio = 3.67 (Total Current Assets 53.7m / Total Current Liabilities 14.6m)
Debt / Equity = 0.46 (Debt 21.0m / totalStockholderEquity, last quarter 45.2m)
Debt / EBITDA = 0.51 (Net Debt 10.0m / EBITDA 19.6m)
Debt / FCF = 1.42 (Net Debt 10.0m / FCF TTM 7.07m)
Total Stockholder Equity = 41.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.24% (Net Income 12.0m / Total Assets 75.0m)
RoE = 29.10% (Net Income TTM 12.0m / Total Stockholder Equity 41.2m)
RoCE = 31.23% (EBIT 17.4m / Capital Employed (Equity 41.2m + L.T.Debt 14.3m))
RoIC = 21.00% (NOPAT 12.9m / Invested Capital 61.6m)
WACC = 6.71% (E(207.5m)/V(228.5m) * Re(7.11%) + D(21.0m)/V(228.5m) * Rd(3.66%) * (1-Tc(0.25)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.43 | Cagr: -4.33%
[DCF] Terminal Value 75.44% ; FCFF base≈7.07m ; Y1≈7.10m ; Y5≈7.52m
[DCF] Fair Price = 33.48 (EV 116.9m - Net Debt 10.0m = Equity 106.9m / Shares 3.19m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 84.03 | EPS CAGR: 89.24% | SUE: 1.68 | # QB: 1
Revenue Correlation: 99.25 | Revenue CAGR: 21.42% | SUE: 3.25 | # QB: 3
EPS current Year (2026-06-30): EPS=2.38 | Chg30d=+0.00% | Revisions=+20% | GrowthEPS=-10.9% | GrowthRev=+14.7%